This hypothesis can also explain the close association between metoclopramide, which acts as a dopamine D2 receptor antagonist, and NMS (Kocyigit et al., 2017; Wittmann et al., 2016). This evidence concerns the gene DRD2 and neuroleptic malignant syndrome.